AstraZeneca sets ambition to deliver $80 billion Total Revenue by …
2024年5月21日 · AstraZeneca’s ambitions, forecasts and targets in this announcement (the “Financial Ambition Statements”) are derived from AstraZeneca’s most recent risk-adjusted mid- and long-term plans, adjusted for developments in the business since those plans were finalised.
AstraZeneca - Research-Based BioPharmaceutical Company
Keep up to date with the latest news Our company has continued on its strong growth trajectory in the first nine months of 2024. Total Revenue and Core EPS were up 21% and 27% respectively in the third quarter, reflecting the increasing demand for our medicines across Oncology, BioPharmaceuticals and Rare Disease and supporting an upgrade to ...
Media Centre - AstraZeneca
2024年11月12日 · AstraZeneca Media centre. The Hub for our Articles, Press Releases and Webcasts & Presentations.
AstraZeneca China President currently under investigation
2024年10月30日 · Leon Wang, Executive Vice President International and AstraZeneca China President, is cooperating with an ongoing investigation by Chinese authorities. Our China operations continue under the leadership of the current General Manager of AstraZeneca China.
AstraZeneca to acquire Fusion to accelerate the development of …
2024年3月19日 · AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer PUBLISHED 19 March 2024 Includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate
Full Year and Q4 2023 results - AstraZeneca
2024年2月8日 · “As AstraZeneca celebrates its 25th anniversary, we are pleased to report another year of strong financial performance and scientific progress, with double-digit earnings growth, and investment in exciting areas of science, including antibody drug conjugates and cell therapies, that lay the foundations for long-term success.
9M and Q3 2023 results - AstraZeneca
2023年11月9日 · Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our company continued its strong growth trajectory in the third quarter with Total Revenue from our non‑COVID-19 medicines up 13% compared to last year.
AstraZeneca to acquire Icosavax, including potential first-in-class …
2023年12月12日 · The proposed acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12.
AstraZeneca launches Evinova, a health-tech business to accelerate ...
2023年11月20日 · AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes PUBLISHED 20 November 2023 Evinova will operate as a …
Imfinzi granted Priority Review and Breakthrough Therapy
2024年8月15日 · AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), based on the results from the positive ADRIATIC Phase III trial in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based concurrent chemoradiotherapy (cCRT), has been accepted and granted ...
- 某些结果已被删除